<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                    FORM 10-Q



     [X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934

              For the quarterly period ended June 30, 2000

     [ ]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934

                  For the transition period from __________ to __________

Commission file number 0-26758

                        ALKERMES CLINICAL PARTNERS, L.P.
             (Exact name of registrant as specified in its charter)

             DELAWARE                                              043-145043
  (State or other jurisdiction of                              (I.R.S. Employer
   incorporation or organization)                           Identification No.)

    64 SIDNEY STREET, CAMBRIDGE, MA                              02139-4136
(Address of principal executive offices)                         (Zip Code)

Registrant's telephone number including area code:  (617) 494-0171

                                 NOT APPLICABLE
 Former name, former address, and former fiscal year, if changed since last
report

         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes __X___ No ___




<PAGE>


                        ALKERMES CLINICAL PARTNERS, L.P.
                             (A LIMITED PARTNERSHIP)

                                      INDEX

                                                                       PAGE NO.

PART I - FINANCIAL INFORMATION

        Item 1.    Financial Statements

                           Balance Sheets                                3
                           -June 30, 2000 and December 31, 1999

                           Statements of Operations                      4
                           -Three months ended June 30, 2000 and 1999
                           -Six months ended June 30, 2000 and 1999

                           Statements of Cash Flows                      5
                           -Six months ended June 30, 2000 and 1999

                           Notes to Financial Statements                 6

        Item 2.    Management's Discussion and Analysis of               8
                   Financial Condition and Results of Operations

PART II - OTHER INFORMATION

        Item 6.    Exhibits, Financial Statement Schedules and Reports   11
                   on Form 8-K

SIGNATURES                                                               12

EXHIBIT INDEX                                                            13




                                      (2)
<PAGE>


ITEM 1.       FINANCIAL STATEMENTS:

                        ALKERMES CLINICAL PARTNERS, L.P.
                            (A Limited Partnership)
                                BALANCE SHEETS
                                  (Unaudited)

                                                    June 30,       December 31,
                                                      2000             1999
                                                  --------------   -------------

                                   A S S E T S

Total Assets                                                $--             $--
                                                  ==============   =============


           L I A B I L I T I E S  A N D  P A R T N E R S'  C A P I T A L


Total Liabilities and Partners' Capital                     $--             $--
                                                  ==============   =============





See notes to financial statements.








                                      (3)
<PAGE>

                        ALKERMES CLINICAL PARTNERS, L.P.
                            (A Limited Partnership)
                            STATEMENTS OF OPERATIONS
                                   (Unaudited)

<TABLE>
<CAPTION>



                                   Three Months    Three Months      Six Months      Six Months
                                      Ended            Ended           Ended           Ended
                                     June 30,        June 30,         June 30,        June 30,
                                       2000            1999             2000            1999
                                   -------------   --------------   -------------   -------------
<S>                                        <C>              <C>             <C>             <C>
Revenue                                     $--              $--             $--             $--
                                   -------------   --------------   -------------   -------------

Expenses:
    General and administrative            3,053            2,695          10,807          20,903
                                   -------------   --------------   -------------   -------------
                                          3,053            2,695          10,807          20,903
                                   -------------   --------------   -------------   -------------

Net loss                                ($3,053)         ($2,695)       ($10,807)       ($20,903)
                                   =============   ==============   =============   =============

Net Loss Per Class A and B Unit             $--              $--             $--             $--
                                   =============   ==============   =============   =============

Average Units Outstanding                   921              921             921             921
                                   =============   ==============   =============   =============



</TABLE>











See notes to financial statements.






                                      (4)
<PAGE>




                        ALKERMES CLINICAL PARTNERS, L.P.
                             (A LIMITED PARTNERSHIP)


                            STATEMENTS OF CASH FLOWS
                                  (Unaudited)

<TABLE>
<CAPTION>



                                                  Six Months     Six Months
                                                    Ended           Ended
                                                   June 30,       June 30,
                                                     2000           1999
                                                 -------------  --------------
<S>                                                 <C>             <C>
Cash flows from operating activities:
   Net loss                                          ($10,807)       ($20,903)

                                                 -------------  --------------
Net cash used for operating activities                (10,807)        (20,903)
                                                 -------------  --------------

Cash flows from financing activities:
   General Partner capital contributions               10,807          20,903
                                                 -------------  --------------


Net change in cash and cash equivalents                    --              --

Cash and cash equivalents, beginning of period             --              --

                                                 =============  ==============
Cash and cash equivalents, end of period                  $--             $--
                                                 =============  ==============


</TABLE>

See notes to financial statements.

                                      (5)
<PAGE>


                        ALKERMES CLINICAL PARTNERS, L.P.
                            (A LIMITED PARTNERSHIP)

                          NOTES TO FINANCIAL STATEMENTS

1.  BASIS OF PRESENTATION

The financial statements for Alkermes Clinical Partners, L.P. (the
"Partnership") for the three and six month periods ended June 30, 2000 and 1999,
are unaudited and include all adjustments which, in the opinion of management,
are necessary to present fairly the results of operations for the periods then
ended. All such adjustments are of a normal recurring nature. These financial
statements should be read in conjunction with the Partnership's Annual Report on
Form 10-K for the year ended December 31, 1999, which includes financial
statements and notes thereto for the years ended December 31, 1999, 1998 and
1997.

The results of the Partnership's operations for any interim period are not
necessarily indicative of the results of the Partnership's operations for any
other interim period or for a full year.

2.  NET LOSS PER CLASS A AND B LIMITED PARTNERSHIP INTEREST

Net loss per Class A and B limited partnership interest is calculated with the
net loss attributable only to the limited partners of the Partnership (each, a
"Limited Partner" and collectively, the "Limited Partners") and excludes the
loss attributable to Alkermes Development Corporation II (the "General
Partner"). There were no losses attributable to the Limited Partners for the
three and six months ended June 30, 2000 and 1999.

3.  COMPLETION OF SCHEDULED FUNDING

For the three and six months ended June 30, 2000 and 1999, the Partnership
incurred no research and development expenses related to the RMP(TM) program,
notwithstanding the continuing development of the product candidate. The
Partnership was providing funding to Alkermes, Inc. ("Alkermes") for research
and development expenses for Cereport(R) from capital contributions received
from Partners. Funding to Alkermes ended during the quarter ended June 30, 1996
when such capital contributions were substantially depleted. None of the
Partners of the Partnership is obligated to make any further capital
contributions. Since the funding was not sufficient for Alkermes to complete
clinical trials and seek regulatory approval of Cereport, Alkermes has used its
own resources, and intends to continue to use its own resources, to develop
Cereport. Alkermes has obtained and intends to continue to obtain such resources
through equity offerings, bank borrowings and its collaborative arrangements.
Alkermes is required to fund the development of Cereport to maintain its
Purchase Option with the Limited Partners.



                                      (6)
<PAGE>


Alkermes is also obligated, through the General Partner, to perform
administrative services for the Partnership, such as preparing financial
statements, tax returns and reports to Partners. Alkermes intends to continue to
cause the General Partner to perform such services at its expense since the
Partnership's current assets are depleted, unless it exercises its Purchase
Option and thereby acquires all the interests in the Partnership. The services
performed by Alkermes and the General Partner constitute all of the activities
undertaken by or on behalf of the Partnership.

After June 30, 2000, the Partnership is expected to have no future liquidity or
capital resources requirements other than those funded by Alkermes.



                                      (7)
<PAGE>


ITEM 2.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
              RESULTS OF OPERATIONS


INTRODUCTION

Alkermes Clinical Partners, L.P. (the "Partnership") was formed on February 7,
1992, and is managed by its general partner, Alkermes Development Corporation II
(the "General Partner"), a wholly owned subsidiary of Alkermes, Inc. ("Alkermes"
or the "Company"). The Partnership was organized to fund the further development
and clinical testing of a family of molecules, designated by Alkermes as
Receptor-Mediated Permeabilizers(TM) ("RMPs(TM)"), for human pharmaceutical use
in the United States and Canada.

IMPORTANT FACTORS REGARDING FORWARD-LOOKING STATEMENTS

Any statements set forth below or otherwise made in writing or orally by the
Partnership or the General Partner with regard to its expectations as to
financial results and other aspects of its business may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
forward-looking words such as "may", "will", "expect", "anticipate", "believe",
"estimate", "continue" or similar words. Although the General Partner believes
that its expectations are based on reasonable assumptions within the bounds of
its knowledge of its business and operations, there can be no assurance that
actual results of the Partnership's or the Company's development activities and
the Partnership's results of operations will not differ materially from its
expectations. Factors which could cause actual results to differ from
expectations include, among others:

(i)      the Partnership and the Company could not be permitted by regulatory
         authorities to undertake additional clinical trials for Cereport(R) or
         clinical trials could be delayed or regulatory authorities could
         require additional clinical trials before approving Cereport;
(ii)     clinical trials for Cereport may not proceed as planned, the trials may
         require more time to enroll patients than anticipated, and even if they
         are completed Cereport could prove to be ineffective or unsafe;
(iii)    the Company could incur difficulties or set-backs in obtaining the
         substantial additional funding required to continue research and
         development programs and clinical trials;
(iv)     the Company could reduce or discontinue funding of Cereport;
(v)      even if Cereport appears promising at an early stage of development, it
         could fail to receive necessary regulatory approvals, be difficult to
         manufacture on a large scale, be uneconomical, fail to achieve market
         acceptance, be precluded from commercialization by proprietary rights
         of third parties or experience substantial competition in the
         marketplace; and
(vi)     technological change in the biotechnology or pharmaceutical industries
         and the approval of other drugs or therapies to treat brain tumors
         could render Cereport obsolete or noncompetitive.



                                      (8)
<PAGE>


RESULTS OF OPERATIONS

REVENUES

The Partnership had no revenue for the three and six months ended June 30, 2000
and 1999. The Partnership anticipates that it will have no revenues in the
foreseeable future.

EXPENSES

The Partnership had no research and development expenses for the three and six
months ended June 30, 2000 and 1999. There were no research and development
expenses because of the completion of the development funding to Alkermes
pursuant to the product development agreement between Alkermes and the
Partnership (the "Product Development Agreement").

General and administrative expenses for the three and six months ended June
30, 2000 were $3,053 and $10,807 as compared to $2,695 and $20,903 for the
three and six months ended June 30, 1999. The increase for the three months
ended June 30, 2000 compared to June 30, 1999 was a result of increased
professional service fees. The decrease for the six months ended June 30,
2000 compared to the six months ended June 30, 1999 was mainly a result of
decreased professional service fees. Alkermes is obligated through the
General Partner to perform general and administrative services for the
Partnership at its expense, unless Alkermes exercises its Purchase Option and
thereby acquires all limited partnership interests in the Partnership (see
Liquidity and Capital Resources).

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2000, the Partnership had no remaining assets or liabilities.

The Partnership's primary source of funding and capital resources had been the
annual capital contributions by the Limited Partners and the General Partner.
The Limited Partners' capital contributions were remitted to the Partnership in
four annual installments, the fourth and final payment of which was due on April
15, 1995. There have been and will be no additional capital contributions
received by the Partnership from the Limited Partners after the quarter ended
June 30, 1996.

The Partnership was funding research and development expenses for Cereport from
capital contributions received from Partners. Such development was and continues
to be conducted for the Partnership by Alkermes pursuant to the Product
Development Agreement. The research and development funding to Alkermes ended
during the quarter ended June 30, 1996 when such capital contributions were
substantially depleted. None of the Partners is obligated to make any further
capital contributions. Because the funding was not sufficient for Alkermes to
complete clinical trials and seek regulatory approval of Cereport, Alkermes has
used its own resources, and intends to continue to obtain such resources through
equity offerings, bank borrowings and its collaborative arrangements. Effective
September 30, 1997, Alkermes entered into an agreement with ALZA Corporation
related to the development and commercialization of Cereport. Alkermes is
required to fund the development of Cereport to maintain its Purchase Option
with the Limited Partners.




                                      (9)
<PAGE>




The Partnership used its remaining cash and cash equivalents during the quarter
ended September 30, 1997 to pay for administrative services for the Partnership.
Alkermes is obligated, through the General Partner, to perform administrative
services for the Partnership, such as preparing financial statements, tax
returns and reports to the Limited Partners. Alkermes intends to continue to
cause the General Partner to perform such services at its expense since the
Partnership's current assets are depleted to maintain its Purchase Option with
the Limited Partners, unless it exercises its Purchase Option and thereby
acquires all limited partnership interests in the Partnership. The activities
performed by Alkermes and the General Partner constitute all of the activities
undertaken by or on behalf of the Partnership.

After June 30, 2000, the Partnership is expected to have no future liquidity or
capital resources requirements other than those funded by Alkermes.




                                      (10)
<PAGE>




ITEM 6.       EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

              (a) Exhibits:

<TABLE>
<CAPTION>

                               NUMBER                                  EXHIBIT
<S>                           <C>               <C>
                               3.1               Alkermes Clinical Partners, L.P. Agreement of Limited
                                                 Partnership, dated as of February 7, 1992.*

                               3.1(a)            Amendment No. 1 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of September 29, 1992.*

                               3.1(b)            Amendment No. 2 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of March 30, 1993.*

                               4.1               Alkermes Clinical Partners, L.P. Agreement of Limited
                                                 Partnership, dated as of February 7, 1992.*

                               4.1(a)            Amendment No. 1 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of September 29, 1992.*

                               4.1(b)            Amendment No. 2 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of March 30, 1993.*

                               27                Financial Data Schedule.

</TABLE>


*  Incorporated by reference to Exhibits to the Registrant's Registration
   Statement on Form 10 filed September 13, 1995.

              (b) During the quarter ended June 30, 2000, the Registrant filed
                  no reports on Form 8-K.



                                      (11)
<PAGE>


                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                              ALKERMES CLINICAL PARTNERS, L.P.
                              (Registrant)

                              By its General Partner

                              ALKERMES DEVELOPMENT CORPORATION II



Date:  August 14, 2000               By: /S/ RICHARD F. POPS
                                        -------------------------------------
                                        Richard F. Pops
                                        Director, President and Chief Executive
                                        Officer (Principal Executive Officer)



Date:  August 14, 2000               By: /S/ JAMES M. FRATES
                                        ------------------------------------
                                         James M. Frates
                                         Director, Vice President, Chief
                                         Financial Officer, Treasurer and
                                         Assistant Secretary (Principal
                                         Financial and Accounting Officer)




                                      (12)
<PAGE>



                                  EXHIBIT INDEX
<TABLE>
<CAPTION>

                               Exhibit
                               NUMBER            DESCRIPTION
<S>                           <C>               <C>
                               3.1               Alkermes Clinical Partners, L.P. Agreement of Limited
                                                 Partnership, dated as of February 7, 1992.*

                               3.1(a)            Amendment No. 1 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of September 29, 1992.*

                               3.1(b)            Amendment No. 2 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of March 30, 1993.*

                               4.1               Alkermes Clinical Partners, L.P. Agreement of Limited
                                                 Partnership, dated as of February 7, 1992.*

                               4.1(a)            Amendment No. 1 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of September 29, 1992.*

                               4.1(b)            Amendment No. 2 to Alkermes Clinical Partners, L.P. Agreement of
                                                 Limited Partnership, dated as of March 30, 1993.*

                               27                Financial Data Schedule.

</TABLE>


*  Incorporated by reference to Exhibits to the Registrant's Registration
   Statement on Form 10 filed September 13, 1995.




                                      (13)